Arcutis Biotherapeutics
ARQT
ARQT
103 hedge funds and large institutions have $1.05B invested in Arcutis Biotherapeutics in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 28 increasing their positions, 33 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
12% less capital invested
Capital invested by funds: $1.19B → $1.05B (-$140M)
15% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 33
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Holders
103
Holding in Top 10
3
Calls
$1.3M
Puts
$506K
Top Buyers
| 1 | +$26.2M | |
| 2 | +$778K | |
| 3 | +$731K | |
| 4 |
Blackstone Inc
New York
|
+$577K |
| 5 |
ACM
Altium Capital Management
New York
|
+$566K |
Top Sellers
| 1 | -$4.19M | |
| 2 | -$2.98M | |
| 3 | -$2.71M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.66M |
| 5 |
Two Sigma Investments
New York
|
-$2.01M |